KR20170135313A - Skin filling material having improved durability and antioxidative activity and the maufacturing method thereof - Google Patents

Skin filling material having improved durability and antioxidative activity and the maufacturing method thereof Download PDF

Info

Publication number
KR20170135313A
KR20170135313A KR1020160067045A KR20160067045A KR20170135313A KR 20170135313 A KR20170135313 A KR 20170135313A KR 1020160067045 A KR1020160067045 A KR 1020160067045A KR 20160067045 A KR20160067045 A KR 20160067045A KR 20170135313 A KR20170135313 A KR 20170135313A
Authority
KR
South Korea
Prior art keywords
carbon atoms
hyaluronic acid
bdde
ha
ether
Prior art date
Application number
KR1020160067045A
Other languages
Korean (ko)
Other versions
KR101866310B1 (en
Inventor
권순익
구현철
Original Assignee
주식회사 글랜젠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 글랜젠 filed Critical 주식회사 글랜젠
Priority to KR1020160067045A priority Critical patent/KR101866310B1/en
Publication of KR20170135313A publication Critical patent/KR20170135313A/en
Application granted granted Critical
Publication of KR101866310B1 publication Critical patent/KR101866310B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/72Cosmetics or similar toilet preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/20Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/06Flowable or injectable implant compositions

Abstract

The present invention relates to a dermal filler composition having improved durability and antioxidation activity in vivo, and a method for producing the same, which has the advantage of improving persistence and antioxidation activity in vivo, as well as an additional function due to an antioxidant effect. The present invention also provides a side effect of improving the skin whitening function by using ascorbyl ether substituted with H of the OH group of carbon number 3 as an antioxidant.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a dermal filler composition having improved durability and antioxidative action in vivo, and a method for producing the same. [0002]

The present invention relates to a dermal filler composition having improved in vivo persistence and antioxidative action and a method for producing the same.

Hyaluronic acid (HA), a glycosaminoglycans present in the dermis, is a biomaterial and is present in about 70 g of body weight, about 15 g of which is present in the skin, especially in connective tissues .

On the other hand, the hyaluronic acid present in the human body has a half-life of about 24 to 48 hours in the body, and about 5 g of the hyaluronic acid is decomposed and produced in the body every day.

Such hyaluronic acid has a high moisture content of about 1,000 times the weight of hyaluronic acid and has the ability to improve the appearance of skin by improving wrinkles caused by soft tissue expansion of skin dermis and is widely used as a moisturizer or skin filler Has been used.

However, hyaluronic acid, which is not cross-linked, has the property of being rapidly degraded by metabolism and catabolism in vivo, and accordingly, hyaluronic acid Lorn acid has been mainly used for crosslinked hyaluronic acid.

Conventionally, crosslinking agents used for crosslinking hyaluronic acid include divinyl sulfone (DVS) (see Patent Document 1 below) or 1,4-butanediol diglycidyl ether (1,4-butanediol diglycidyl ether, BDDE) (see Patent Document 2 below) has been used.

On the other hand, hyaluronic acid crosslinked with DVS or BDDE crosslinking agent also has a disadvantage in that the persistence in vivo is about 6 to 12 months or less, which is relatively inferior in persistence. In order to overcome such disadvantages, a method of increasing the persistence of hyaluronic acid in vivo through simple mixing of crosslinked hyaluronic acid with an antioxidant has been used. Examples of the antioxidant used in this case include vitamin C and its derivatives Reference 3) and uric acid (see Patent Document 4 below).

However, such an antioxidant has antioxidant activity and inhibits polysaccharide decomposition. When used as a dermal filler, it can increase the persistence of hyaluronic acid in vivo to a certain extent. However, when such an antioxidant is simply mixed with crosslinked hyaluronic acid The effect thereof is very low.

In order to overcome these disadvantages, Patent Document 5 discloses a case in which a hyaluronic acid derivative in which vitamin C is directly covalently bonded to hyaluronic acid is prepared and applied to atopic dermatitis. In Patent Document 6, vitamin C and vitamin C derivatives are dissolved in hyaluronic acid The present invention discloses a hyaluronic acid-based hydrogel composition prepared by covalently bonding conjugated dicarboxylic acid to lonic acid, and has been applied as an injectable dermal filler, and mainly discloses vitamin C derivatives such as L-ascorbic acid 2-glucoside, Phosphate or sodium ascorbyl phosphate was used.

Vitamin C, which is very effective as an antioxidant, has been continuously developed for various types of vitamin C derivatives because of its poor oxidation stability. Most of the vitamin C derivatives have a substitution form with the hydrogen of the hydroxyl of the carbon at the second position of vitamin C, and vitamin C derivatives such as L-ascorbic acid 2-glucoside, ascorbyl 3-aminopropyl phosphate And sodium ascorbyl phosphate also take the form substituted with the hydrogen of the hydroxyl of the carbon at the second position of vitamin C. However, the hydrogen of the hydroxyl group of the second carbon of vitamin C and the substituted vitamin C derivative have a problem that their stability is poor.

Therefore, there is an urgent need to develop a novel hyaluronic acid dermal filler composition for further improving in vivo persistence.

Patent Document 1: U.S. Patent No. 4,582,865 Patent Document 2: U.S. Patent No. 5,827,937 Patent Document 3: European Patent No. 2484387 Al Patent Document 4: Korean Patent No. 10-1459070 Patent Document 5: Korean Patent No. 10-1122163 Patent Document 6: U.S. Patent No. 9,149,422

Accordingly, in order to solve the above problems, the present invention provides a method for producing a biodegradable polyester resin by using an ascorbyl ether such as hyaluronic acid (HA), 1,4-butanediol diglycidyl ether (BDDE) and 3-O-ethyl ascorbyl ether (VCE) The present inventors have found that a dermal filler composition having excellent durability, antioxidative action and persistence of polysaccharide decomposition inhibiting effect can be prepared, and the present invention has been completed on the basis thereof.

Accordingly, one aspect of the present invention is to provide a dermal filler composition which is excellent in persistence in vivo, antioxidative action, and persistence of polysaccharide decomposition inhibitory effect.

Another aspect of the present invention is to provide a method for producing the dermal filler composition.

The dermal filler composition according to one embodiment of the present invention comprises hyaluronic acid (HA), 1,4-butanediol diglycidyl ether (BDDE)

[Chemical Formula 1]

Figure pat00001

Lt; RTI ID = 0.0 > of < / RTI >

Here, R represents a linear or branched saturated alkyl (having 1 to 30 carbon atoms), an alkenyl (having 1 to 30 carbon atoms), an alkynyl (having 1 to 30 carbon atoms, an alkylcarbonyl having 2 to 29 carbon atoms, (Having 1 to 30 carbon atoms), alkyl (having 1 to 30 carbon atoms), aryl (having 6 to 30 carbon atoms), cycloalkyl (having 3 to 30 carbon atoms), alkoxy ) Aryl (having from 6 to 30 carbon atoms).

In a dermal filler composition according to another embodiment of the present invention, the ascorbyl ether may be 3-O-ethyl ascorbyl ether.

In the dermal filler composition according to another embodiment of the present invention, the hyaluronic acid (HA) and the ascorbyl ether or hyaluronic acid (HA) may be cross-linked by the BDDE.

In a dermal filler composition according to another embodiment of the present invention, the ascorbyl ether is cross-linked to one hyaluronic acid (HA) by BDDE, and one of the hyaluronic acid (HA) And can be cross-linked by BDDE.

In the dermal filler composition according to another embodiment of the present invention, the 1,4-butanediol diglycidyl ether (BDDE) is contained at a ratio of 0.01 mole to 1 mole per 1 mole of the hyaluronic acid (HA) The ascorbyl ether may be contained in an amount of 0.01 mole to 1 mole per mole of the hyaluronic acid (HA) repeating unit.

A method for preparing a dermal filler composition according to an embodiment of the present invention comprises mixing 1,4-butanediol diglycidyl ether (BDDE)

[Chemical Formula 1]

Figure pat00002

To form a BDDE-ascorbyl ether complex; And a complex in which the hyaluronic acid to which the ascorbyl ether is bonded is cross-linked with another hyaluronic acid by reacting the BDDE-ascorbyl ether complex with hyaluronic acid (HA) and 1,4-butanediol diglycidyl ether (BDDE) Wherein R is selected from the group consisting of linear or branched saturated alkyl (having 1 to 30 carbon atoms), alkenyl (having 1 to 30 carbon atoms), alkynyl (having 1 to 30 carbon atoms), alkylcarbonyl (Having from 1 to 30 carbon atoms), aryl (having from 6 to 30 carbon atoms), alkyl (having from 1 to 30 carbon atoms) aryl (having from 6 to 30 carbon atoms), cycloalkyl (having from 3 to 30 carbon atoms) To 30), and alkoxy (having 1 to 30 carbon atoms) aryl (having 6 to 30 carbon atoms).

In another embodiment of the present invention, the ascorbyl ether may be 3-O-ethyl ascorbyl ether.

The dermal filler composition according to the present invention has an advantage of improving in vivo persistence and antioxidative action. That is, when the dermal filler composition according to the present invention is inserted into the body using a dermal filler, the duration of the dermal filler composition can be extended up to 2 years. In addition, the present invention has an advantage that 3-O-ethyl ascorbyl ether can be used to slow down metabolism of hyaluronic acid in the body, and 3-O-ethyl ascorbyl ether, which is an antioxidant, It not only enhances the function of the hyaluronic acid as a dermis filler but also has the advantage of adding the function due to the antioxidant effect. In addition, 3-O-ethyl ascorbyl ether, which is an antioxidant, is a material that becomes a material of skin whitening functional cosmetics and exhibits a side effect of improving skin whitening function in addition to antioxidant effect.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a diagram illustrating a process for preparing a dermal filler composition according to the present invention. FIG.

Before describing the invention in more detail, it is to be understood that the words or words used in the specification and claims are not to be construed in a conventional or dictionary sense, It should be interpreted as meaning and concept consistent with the technical idea of the present invention. Therefore, the constitution of the embodiments described in the present specification is merely a preferred example of the present invention, and does not represent all the technical ideas of the present invention, so that various equivalents and variations And the like.

Hereinafter, preferred embodiments of the present invention will be described in detail so that those skilled in the art can easily carry out the present invention.

The present invention relates to a dermal filler composition having improved durability and antioxidation activity in vivo, and a method for producing the same. More specifically, the present invention relates to a dermal filler composition having improved durability and antioxidation activity in vivo, To a dermal filler composition having a skin whitening function, and a method for producing the dermal filler composition.

The dermal filler composition according to one embodiment of the present invention comprises hyaluronic acid (HA), 1,4-butanediol diglycidyl ether (BDDE)

[Chemical Formula 1]

Figure pat00003

Lt; RTI ID = 0.0 > of < / RTI >

Here, R represents a linear or branched saturated alkyl (having 1 to 30 carbon atoms), an alkenyl (having 1 to 30 carbon atoms), an alkynyl (having 1 to 30 carbon atoms, an alkylcarbonyl having 2 to 29 carbon atoms, (Having 1 to 30 carbon atoms), alkyl (having 1 to 30 carbon atoms), aryl (having 6 to 30 carbon atoms), cycloalkyl (having 3 to 30 carbon atoms), alkoxy ) Aryl (having from 6 to 30 carbon atoms).

The above-mentioned ascorbyl ether used in the present invention is characterized in that the H of the OH group located at the carbon number 3 is substituted with any of the above-mentioned functional groups. Thus, when the H of the OH group located at the carbon number 3 is the above- The present invention is not limited to these examples, and all of the technical ideas using ascorbyl ether substituted with any one of them are to be construed as being included in the scope of the present invention.

For example, the ascorbyl ether may be 3-O-ethyl ascorbyl ether (VCE).

The ascorbyl ether is a vitamin C derivative for improving the in vivo persistence of hyaluronic acid. On the other hand, it plays an antioxidant role and a polysaccharide decomposition inhibitory role (a role of increasing the duration of the dermal filler in the body).

The ascorbyl ether is a hydrogenated and substituted vitamin C derivative of the hydroxyl group of the third carbon of vitamin C, which is superior in stability. The ascorbyl ether-bonded hyaluronic acid derivative is bound to the ascorbyl ether It exhibits excellent stability and is excellent in antioxidant activity and persistence effect of polysaccharide decomposition inhibiting effect in the body.

The hyaluronic acid (HA) is a glycosaminoglycans present in the dermal layer and is the main structural component of the dermal filler. This is a biocompatible material in which about 15 g is present in a human body having a body weight of about 70 kg, of which 50% is present in the skin, particularly the connective tissue, and has a repeating unit represented by the following formula (2).

(2)

Figure pat00004

On the other hand, the hyaluronic acid present in the human body has a half-life of about 24 to 48 hours in the body, and about 5 g of the hyaluronic acid is decomposed and produced in the body every day.

The 1,4-butanediol diglycidyl ether (BDDE) functions as a crosslinking agent responsible for crosslinking between 3-O-ethyl ascorbyl ether (VCE) and hyaluronic acid and cross-linking between hyaluronic acid, 3 < / RTI >

(3)

Figure pat00005

Meanwhile, the mutual interactions between hyaluronic acid (HA) and ascorbyl ether or hyaluronic acid (HA) may be crosslinked by the BDDE, and the ascorbyl ether may be cross-linked to any hyaluronic acid (HA) And one of the hyaluronic acid (HA) can be cross-linked by another hyaluronic acid (HA) and BDDE.

Meanwhile, the 1,4-butanediol diglycidyl ether (BDDE) is contained in an amount of 0.01 mole to 1 mole per mole of the hyaluronic acid (HA) repeating unit, and the ascorbyl ether is the hyaluronic acid (HA) repeating unit May be contained at a ratio of 0.01 mole to 1 mole per mole.

If the content of the hyaluronic acid is less than the above-mentioned content ratio, the dermal filler does not function properly. If the content of the hyaluronic acid exceeds the above-mentioned content ratio, it is difficult to insert the hyaluronic acid into the body with the syringe.

On the other hand, when the content ratio of the 1,4-butanediol diglycidyl ether (BDDE) is less than the above range, the duration of the dermal filler is decreased due to the low degree of crosslinking and the antioxidant and polysaccharide decomposition inhibiting function is lowered There is a problem that it is lost, and if it exceeds the above content range, the degree of crosslinking becomes high, so that it is difficult to insert the filler into the body and a foreign body feeling may be felt.

On the other hand, when the content of the ascorbyl ether is less than the above range, the antioxidant and polysaccharide decomposition inhibiting function may be lost. When the content exceeds the above range, the degree of crosslinking of the crosslinking agent may be lowered, and the binding with hyaluronic acid There is a problem that becomes difficult.

Meanwhile, a method for preparing a dermal filler composition according to an embodiment of the present invention comprises mixing 1,4-butanediol diglycidyl ether (BDDE)

[Chemical Formula 1]

Figure pat00006

To form a BDDE-ascorbyl ether complex; And a complex in which the hyaluronic acid to which the ascorbyl ether is bonded is cross-linked with another hyaluronic acid by reacting the BDDE-ascorbyl ether complex with hyaluronic acid (HA) and 1,4-butanediol diglycidyl ether (BDDE) Wherein R is selected from the group consisting of linear or branched saturated alkyl (having 1 to 30 carbon atoms), alkenyl (having 1 to 30 carbon atoms), alkynyl (having 1 to 30 carbon atoms), alkylcarbonyl (Having from 1 to 30 carbon atoms), aryl (having from 6 to 30 carbon atoms), alkyl (having from 1 to 30 carbon atoms) aryl (having from 6 to 30 carbon atoms), cycloalkyl (having from 3 to 30 carbon atoms) To 30), and alkoxy (having 1 to 30 carbon atoms) aryl (having 6 to 30 carbon atoms).

The ascorbyl ether may be 3-O-ethyl ascorbyl ether (VCE).

FIG. 1 illustrates a specific reaction process diagram for preparing a dermal filler composition according to an embodiment of the present invention using 3-O-ethyl ascorbyl ether.

Referring to FIG. 1, BDDE used as a crosslinking agent reacts with VCE to form VCE-BDDE. Then, the thus formed VCE-BDDE reacts with hyaluronic acid, and the BDDE contained therein acts as a cross-linking agent of hyaluronic acid to finally obtain cross-linked hyaluronic acid having VCE bonded thereto.

Hereinafter, a specific process for preparing the dermal filler composition according to the present invention will be described with reference to the following examples. Various comparative examples in which the effects of the present invention can be comparatively confirmed will be described. However, the scope of the present invention is not limited to the following examples.

Example 1

9.3 g of 3-O-ethyl ascorbyl ether and 6.7 g of BDDE were mixed in an aqueous solution of 15.4 g of NaOH 2.4 wt% and reacted at 40 캜. To the aqueous solution of 24.3 g of NaOH 0.9 wt%, 4.9 g of The solution in which hyaluronic acid was dissolved was added and shaken very slowly for 4 hours in an incubator at 40 ° C. To this was added 11.4 ml of 3.5 M HCl in 5 M HCl to form a hydrogel, which was slowly shaken at room temperature for 4 hours. The thus-formed hydrogel was placed in a polyalisis bag, and dialysis was carried out in a neutral PBS solution for 300 hours. After completion of the dialysis, it was stored in a refrigerator.

Comparative Example 1

9.3 g of L-ascorbic acid 2-glucoside and 6.7 g of BDDE were mixed in an aqueous solution of 15.4 g of NaOH 2.4 wt% and reacted at 40 캜. To the aqueous solution of 24.3 g of NaOH 0.9 wt%, 4.9 g of The solution in which hyaluronic acid was dissolved was added and shaken very slowly for 4 hours in an incubator at 40 ° C. To this was added 11.4 ml of 3.5 M HCl in 5 M HCl to form a hydrogel, which was slowly shaken at room temperature for 4 hours. The thus-formed hydrogel was placed in a polyalisis bag, and dialysis was carried out in a neutral PBS solution for 300 hours. After completion of the dialysis, it was stored in a refrigerator.

Comparative Example 2

To 15.4 g of an aqueous solution of 2.4% by weight of NaOH, 9.3 g of ascorbyl 3-aminopropyl phosphate and 6.7 g of BDDE were mixed and reacted at 40 캜. To the aqueous solution of 24.3 g of 0.9 wt% of NaOH was added 4.9 g of hyaluronic acid Lonic acid was added to the solution, which was slowly shaken in an incubator at 40 ° C for 4 hours. To this was added 11.4 ml of 3.5 M HCl in 5 M HCl to form a hydrogel, which was slowly shaken at room temperature for 4 hours. The thus-formed hydrogel was placed in a polyalisis bag, and dialysis was carried out in a neutral PBS solution for 300 hours. After completion of the dialysis, it was stored in a refrigerator.

Comparative Example 3

9.3 g of sodium ascorbyl phosphate and 6.7 g of BDDE were mixed in an aqueous solution of 15.4 g of NaOH 2.4 wt% and reacted at 40 DEG C. To this was added 4.9 g of hyaluronic acid into 24.3 g of an aqueous solution of 0.9 wt% of NaOH The dissolved solution was added and shaken very slowly for 4 hours in an incubator at 40 ° C. To this was added 11.4 ml of 3.5 M HCl in 5 M HCl to form a hydrogel, which was slowly shaken at room temperature for 4 hours. The thus-formed hydrogel was placed in a polyalisis bag, and dialysis was performed in a neutral PBS solution for 300 hours. After completion of the polyalysis, it was stored in a refrigerator.

[In vivo persistence experiment]

10 months old mouse ( Mus musculus) hyaluronic not described in Example 1 and Comparative Examples 1 to 3 The dermal filling material and made according to the cross-linking across the area was anesthetized with 15 females, 3㎝ × 3㎝ vertical abdomen of the mice, respectively Length × acid ( (Control 1 to 3, mouse 4 to 6: Example 1, mouse 7 to 9: comparative example 1, mouse 10 to 10 mice) were divided into five groups of 20 mg each by a syringe. 12: Comparative Example 2, Mice 13 to 15: Comparative Example 3). Thereafter, 1 ml of each of the abdominal dermis samples was taken in an anesthesia state at 1 week, 1 month, 2 months, 3 months, and 6 months respectively, and the concentration of hyaluronic acid was measured. The results are shown in Table 1 .

division mouse 1 week 1 month 2 months 3 months 6 months Control 1 One 25 15 10 2 0 Control 2 2 24 12 8 2 0 Control 3 3 26 14 9 2 0 Example 1 4 30 30 29 28 25 Example 1 5 32 31 29 28 25 Example 1 6 32 31 30 29 25 Comparative Example 1 7 30 25 20 15 5 Comparative Example 1 8 32 24 19 14 4 Comparative Example 1 9 30 23 21 15 4 Comparative Example 2 10 30 23 18 14 5 Comparative Example 2 11 30 24 19 13 4 Comparative Example 2 12 32 25 20 15 3 Comparative Example 3 13 30 23 18 15 5 Comparative Example 3 14 31 25 20 14 4 Comparative Example 3 15 30 25 20 13 5

(Unit: 占 퐂 / ml)

As shown in the results of Table 1, it can be confirmed that the concentration of hyaluronic acid in the dermis rapidly decreases over time in the case of unhybridized hyaluronic acid (Controls 1 to 3).

On the other hand, Comparative Examples 1 to 3 (mice 7 to 15) using L-ascorbic acid 2-glucoside, ascorbyl 3-aminopropyl phosphate, and sodium ascorbyl phosphate showed stable persistence in the mouse dermis , It can be confirmed that it is remarkably low in persistence as compared with Example 1 (mice 4 to 6) of the present invention.

Therefore, the results of Table 1 can be interpreted as indicating excellent dermal consistency of the dermal filler composition according to the present invention.

[Skin aging test]

10 months old mouse ( Mus musculus) hyaluronic not described in Example 1 and Comparative Examples 1 to 3 The dermal filling material and made according to the cross-linking across the area was anesthetized with 15 females, 3㎝ × 3㎝ vertical abdomen of the mice, respectively Length × acid ( (Control 1 to 3, mouse 4 to 6: Example 1, mouse 7 to 9: comparative example 1, mouse 10 to 10 mice) were divided into five groups of 20 mg each by a syringe. 12: Comparative Example 2, Mice 13 to 15: Comparative Example 3). Thereafter, the total length of the wrinkles formed at the site where the sample was injected under anesthesia was measured at 1 week, 1 month, 2 months, 3 months, and 6 months, respectively, to confirm the skin aging degree. Table 2 shows the results.

division mouse 1 week 1 month 2 months 3 months 6 months Control 1 One 0 One 3 5 8 Control 2 2 0 One 3 5 9 Control 3 3 0 2 4 6 8 Example 1 4 0 0 0 0 0 Example 1 5 0 0 0 0 0 Example 1 6 0 0 0 0 0 Comparative Example 1 7 0 0 0 2 3 Comparative Example 1 8 0 0 0 2 4 Comparative Example 1 9 0 0 0 One 3 Comparative Example 2 10 0 0 0 2 3 Comparative Example 2 11 0 0 0 2 3 Comparative Example 2 12 0 0 0 2 3 Comparative Example 3 13 0 0 0 2 4 Comparative Example 3 14 0 0 0 2 4 Comparative Example 3 15 0 0 0 2 4

(Unit: cm)

As can be seen from the results of Table 2, it can be seen that the total length of the wrinkles of the skin relatively increased with time when the non-crosslinked hyaluronic acid was injected (Controls 1 to 3).

On the other hand, in the case of Comparative Examples 1 to 3 (mice 7 to 15) using L-ascorbic acid 2-glucoside, ascorbyl 3-aminopropyl phosphate and sodium ascorbyl phosphate, However, in Example 1 (mice 4 to 6) of the present invention, it is confirmed that the skin aging prevention effect is remarkably low as compared with the case where wrinkles are not observed at all for 6 months.

Accordingly, the results of Table 2 can be interpreted as indicating the excellent durability of antioxidative action of the dermal filler composition according to the present invention.

[Skin toxicity test]

10 months old mouse ( Mus musculus) hyaluronic not described in Example 1 and Comparative Examples 1 to 3 The dermal filling material and made according to the cross-linking across the area was anesthetized with 15 females, 3㎝ × 3㎝ vertical abdomen of the mice, respectively Length × acid ( (Control 1 to 3, mouse 4 to 6: Example 1, mouse 7 to 9: comparative example 1, mouse 10 to 10 mice) were divided into five groups of 20 mg each by a syringe. 12: Comparative Example 2, Mice 13 to 15: Comparative Example 3). Thereafter, skin conditions such as skin rash, discoloration, and tumor formation of the abdominal skin were visually observed in the state of anesthetizing mice 1 to 15 after one week, one month, two months, three months, and six months, respectively, And the results are shown in Table 3 below.

division mouse 1 week 1 month 2 months 3 months 6 months Control 1 - - - - - - Control 2 - - - - - - Control 3 - - - - - - Example 1 - - - - - - Example 1 - - - - - - Example 1 - - - - - - Comparative Example 1 - - - - - - Comparative Example 1 - - - - - - Comparative Example 1 - - - - - - Comparative Example 2 - - - - - - Comparative Example 2 - - - - - - Comparative Example 2 - - - - - - Comparative Example 3 - - - - - - Comparative Example 3 - - - - - - Comparative Example 3 - - - - - -

(+: Skin abnormality, -: No skin abnormality)

In the results of Table 3, no skin abnormality due to the injection of the sample was observed in the abdominal dermis layer during the passage of 6 months in the Controls 1 to 3, Example 1 and Comparative Examples 1 to 3.

Therefore, the results of Table 3 above can be interpreted as supporting the biosafety of the dermal filler composition according to the present invention.

Claims (7)

  1. Hyaluronic acid (HA), 1,4-butanediol diglycidyl ether (BDDE) and the following formula 1;
    [Chemical Formula 1]
    Figure pat00007

    Lt; RTI ID = 0.0 > of < / RTI >
    Here, R represents a linear or branched saturated alkyl (having 1 to 30 carbon atoms), an alkenyl (having 1 to 30 carbon atoms), an alkynyl (having 1 to 30 carbon atoms, an alkylcarbonyl having 2 to 29 carbon atoms, (Having 1 to 30 carbon atoms), alkyl (having 1 to 30 carbon atoms), aryl (having 6 to 30 carbon atoms), cycloalkyl (having 3 to 30 carbon atoms), alkoxy ) Aryl (having 6 to 30 carbon atoms), which has improved persistence and antioxidative activity in vivo.
  2. The method according to claim 1,
    Wherein the ascorbyl ether is 3-O-ethyl ascorbyl ether and has improved in vivo persistence and antioxidant activity.
  3. The method according to claim 1,
    The mutual interactions between hyaluronic acid (HA) and ascorbyl ether or between hyaluronic acid (HA) are cross-linked by 1,4-butanediol diglycidyl ether (BDDE) Composition.
  4. The method according to claim 1,
    Wherein the ascorbyl ether is crosslinked to one hyaluronic acid (HA) by 1,4-butanediol diglycidyl ether (BDDE), and the one hyaluronic acid (HA) is crosslinked with another hyaluronic acid (HA) A dermal filler composition crosslinked by 4-butanediol diglycidyl ether (BDDE) and improved in vivo persistence and antioxidant activity.
  5. The method according to claim 1,
    The 1,4-butanediol diglycidyl ether (BDDE) is contained at a ratio of 0.01 mol to 1 mol per 1 mol of the hyaluronic acid (HA) repeating unit, and the ascorbyl ether is contained per 1 mol of the hyaluronic acid (HA) 0.01 to 1 mol ratio, and the dermal filler composition has improved in vivo persistence and antioxidant activity.
  6. 1,4-butanediol diglycidyl ether (BDDE) and the following formula 1;
    [Chemical Formula 1]
    Figure pat00008

    To form a BDDE-ascorbyl ether complex; And
    The BDDE-ascorbyl ether complex is reacted with hyaluronic acid (HA) and 1,4-butanediol diglycidyl ether (BDDE) to form a complex in which ascorbyl ether-bonded hyaluronic acid is crosslinked with another hyaluronic acid And a second step of forming,
    Here, R represents a linear or branched saturated alkyl (having 1 to 30 carbon atoms), an alkenyl (having 1 to 30 carbon atoms), an alkynyl (having 1 to 30 carbon atoms, an alkylcarbonyl having 2 to 29 carbon atoms, (Having 1 to 30 carbon atoms), alkyl (having 1 to 30 carbon atoms), aryl (having 6 to 30 carbon atoms), cycloalkyl (having 3 to 30 carbon atoms), alkoxy ) Aryl (having from 6 to 30 carbon atoms).
  7. The method of claim 6,
    Wherein the ascorbyl ether is 3-O-ethyl ascorbyl ether.
KR1020160067045A 2016-05-31 2016-05-31 Skin filling material having improved durability and antioxidative activity and the maufacturing method thereof KR101866310B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020160067045A KR101866310B1 (en) 2016-05-31 2016-05-31 Skin filling material having improved durability and antioxidative activity and the maufacturing method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160067045A KR101866310B1 (en) 2016-05-31 2016-05-31 Skin filling material having improved durability and antioxidative activity and the maufacturing method thereof

Publications (2)

Publication Number Publication Date
KR20170135313A true KR20170135313A (en) 2017-12-08
KR101866310B1 KR101866310B1 (en) 2018-06-11

Family

ID=60920007

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160067045A KR101866310B1 (en) 2016-05-31 2016-05-31 Skin filling material having improved durability and antioxidative activity and the maufacturing method thereof

Country Status (1)

Country Link
KR (1) KR101866310B1 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
KR100485727B1 (en) * 2004-06-24 2005-04-19 주식회사 바이오리더스 Poly-gamma-glutamic acid-vitamin complex and use thereof
KR20090043651A (en) * 2007-10-30 2009-05-07 (주)바이오제닉스 Aqueous cosmetic composition comprising coated antioxidant particle and method for preparing the particle
KR101122163B1 (en) 2009-12-01 2012-03-16 (주)셀인바이오 Hyaluronic acid derivative with atopic dermatitis treating effect and method of preparing the same
EP2484387A1 (en) 2011-02-03 2012-08-08 Q-Med AB Hyaluronic acid composition
KR20140072008A (en) * 2011-06-03 2014-06-12 알러간, 인코포레이티드 Dermal filler compositions including antioxidants
KR20140078149A (en) * 2012-12-17 2014-06-25 코웨이 주식회사 Make up cosmetic composition with transparent appearance and covering pore and wrinkle
KR101459070B1 (en) 2013-12-09 2014-11-17 (주) 뉴메딕 Long lasting crosslinked polysaccharide gel formulation
KR20150143311A (en) * 2014-06-11 2015-12-23 주식회사 엘앤씨바이오 Manufacturing method of bio-graft or bio-implant compositions comprising crosslinkied acellular dermal matrix

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US5827937A (en) 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
KR100485727B1 (en) * 2004-06-24 2005-04-19 주식회사 바이오리더스 Poly-gamma-glutamic acid-vitamin complex and use thereof
KR20090043651A (en) * 2007-10-30 2009-05-07 (주)바이오제닉스 Aqueous cosmetic composition comprising coated antioxidant particle and method for preparing the particle
KR101122163B1 (en) 2009-12-01 2012-03-16 (주)셀인바이오 Hyaluronic acid derivative with atopic dermatitis treating effect and method of preparing the same
EP2484387A1 (en) 2011-02-03 2012-08-08 Q-Med AB Hyaluronic acid composition
KR20140049967A (en) * 2011-02-03 2014-04-28 큐-메드 에이비 Hyaluronic acid composition
KR20140072008A (en) * 2011-06-03 2014-06-12 알러간, 인코포레이티드 Dermal filler compositions including antioxidants
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
KR20140078149A (en) * 2012-12-17 2014-06-25 코웨이 주식회사 Make up cosmetic composition with transparent appearance and covering pore and wrinkle
KR101459070B1 (en) 2013-12-09 2014-11-17 (주) 뉴메딕 Long lasting crosslinked polysaccharide gel formulation
KR20150143311A (en) * 2014-06-11 2015-12-23 주식회사 엘앤씨바이오 Manufacturing method of bio-graft or bio-implant compositions comprising crosslinkied acellular dermal matrix

Also Published As

Publication number Publication date
KR101866310B1 (en) 2018-06-11

Similar Documents

Publication Publication Date Title
US8784893B2 (en) Polymer formulations for delivery of bioactive agents
US4851521A (en) Esters of hyaluronic acid
CA1244590A (en) Reactive polymers for dermal and transdermal therapy
KR101387294B1 (en) Silicone polyether elastomer gels
KR101554758B1 (en) Polysaccharide gel formulation
EP1144459B2 (en) Cross-linked hyaluronic acids and medical uses thereof
US20050226936A1 (en) Method of soft tissue augmentation
ES2227297T3 (en) New cross-linked derivatives of hyaluronic acid.
TWI430815B (en) Hyaluronic acid gel for intradermal injection
DE69629408T2 (en) absorbable polyoxaester
CA2170754C (en) Injectable compositions for soft tissue augmentation
US20050266083A1 (en) Vehicles for delivery of biologically active substances
US20040047892A1 (en) Filler composition for soft tissue augmentation and reconstructive surgery
EP2121026B1 (en) Novel injectable chitosan mixtures forming hydrogels
US20060246137A1 (en) Complex matrix for biomedical use
Chiellini et al. Perspectives on alternatives to phthalate plasticized poly (vinyl chloride) in medical devices applications
ES2556475T3 (en) injectable composition based on hyaluronic acid, polyol (s) and lidocaine, heat sterilized
US10207024B2 (en) Biodegradable single-phase cohesive hydrogels
US10220113B2 (en) Heat stable hyaluronic acid compositions for dermatological use
EP0713707A1 (en) In situ crosslinkable, injectable collagen composition for tissue augmention
AU2005219595B2 (en) Biocompatible crosslinked gel
CN103702659B (en) Antioxidants including dermal filler composition
EP2620138B1 (en) Foam-type external skin preparation
MX2007000883A (en) Insulin-oligomer conjugates, formulations and uses thereof.
BR0215517A (en) antiseptic composition, and methods for disinfecting tissue and to produce an antiseptic composition

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant